Septic Arthritis Market is Increasing Patient Population Expected to Support Growth Over 2023

Pune, India, June 2019, MRFR Press Release/- Market Research Future has Published a Half-Cooked Research Report on the Global Septic Arthritis Market.

Market Synopsis:

Septic arthritis has been witnessing a rise in patient population which has led to the generation of demand for effective drugs and treatments. Market Research Future (MRFR)’s assessment reveals that the global septic arthritis market has been projected to strike a CAGR of 7.5% across the forecast period 2017 to 2023. People with diabetes, rheumatoid arthritis, and obesity are more prone to developing septic arthritis. Thus, the increasing patient population of these diseases is expected to catapult the market on an upward trajectory.

Healthcare industry leaders are investing in research & development of new drugs and treatments. This, in turn, is projected to have a favorable influence on the expansion of the septic arthritis market over the next couple of years. The increasing population of older adults is expected to catalyze the growth of the market in the foreseeable future owing to increasing joint replacement surgeries among them. People who have undergone knee replacement or hip replacement are more likely to develop septic arthritis. It is poised to accelerate revenue generation of the market through the assessment period.

Market Segmentation:

On the basis of diagnosis, the global septic arthritis market has been segmented into joint fluid analysis, imaging, blood tests, and others. The imaging segment is further sub-segmented into X-ray, MRI, ultrasonography, and CT scan.

Based on treatment, the septic arthritis market has been segmented into aspiration of the joint, antibiotics, surgery, and others. The surgery segment has been further sub-segmented into arthrotomy and arthroscopy.

By indication, the global septic arthritis market has been segmented into joint surgery, hip or knee prosthesis, arthritis, poor immune function, and others.

On the basis of end-user, the septic arthritis market has been segmented into orthopedic hospitals, pharmaceutical companies, clinics, and others.

Browse Full Report Details @ https://www.marketresearchfuture.com/reports/septic-arthritis-market-4603

Competitive Dashboard:

The important players profiled in the share analysis of the septic arthritis market are Lupin Pharmaceuticals, Inc. (U.S.), AbbVie Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Amgen Inc. (U.S.), Johnson & Johnson Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), and Pfizer (U.S.).

Regional Analysis

By region, the global septic arthritis market has been segmented into Americas, Asia Pacific, Europe, and the Middle East & Africa (MEA). Americas is the largest market for septic arthritis and is anticipated to exhibit a moderate CAGR over the next couple of years. The U.S. is expected to contribute significantly towards the development of the septic arthritis market in the region owing to the rising burden of the disease. In addition, the increasing prevalence of obesity is also likely to intensify the burden of septic arthritis in the region in the foreseeable future. According to the facts presented by the Center for Disease Control and Prevention, approximately 78 million adults (18 years & above) are expected to have diagnosed arthritis by 2040.

Europe holds the second spot in the global marketplace and signifies developmental opportunities. The rising efforts directed towards research & development of more effective drugs is anticipated to catapult the septic arthritis market in the regional market on an upward trajectory.

Asia Pacific is projected to expand at the fastest pace in the years to come. Septic arthritis is likely to affect a comparatively higher fraction of population in the nearby future owing to the rising prevalence of diabetes and obesity. Other factors such as a rising population of older adults, changes in lifestyle, etc. are anticipated to support the growth pattern of the septic arthritis market over the next couple of years. The Middle East & Africa (MEA) is projected to expand at a steady but constant rate due to the increasing patient population.

Industry News:

In May 2019, the U.S. Food & Drug Administration (FDA) has granted approval to Synovasure Lateral Flow Test Kit which is designed for the detection of periprosthetic joint infection that affects joint replacement. The kit is manufactured by CD Diagnostics, acquired by Zimmer Biomet.